Resveratrol Bioavailability

The red wine molecule that disappears after it gets in

The odd part about resveratrol is not that the gut refuses it. In human studies, oral resveratrol is absorbed fairly well. One review reports oral absorption around 75 percent, but oral bioavailability of unchanged resveratrol at considerably less than 1 percent because the intestine and liver rapidly alter it before much free resveratrol circulates in the blood. That is the specific trap: absorption and bioavailability are not the same question.

Absorption asks, “Did it cross from the gut into the body?” Bioavailability asks, “How much of the original, unchanged compound reached the bloodstream where it can travel around?” Resveratrol often clears the first hurdle, then changes form quickly.

What the body does to resveratrol

After you swallow resveratrol, cells in the gut wall and liver attach small chemical tags to it. The main tagged forms are called glucuronides and sulfates. In plain language, those tags make resveratrol easier to move through water and remove in urine or bile. They also mean the blood may contain far more tagged resveratrol than free resveratrol.

This is why a capsule can contain 500 mg of trans-resveratrol while blood tests show only tiny amounts of unchanged resveratrol. The dose did not necessarily “fail to absorb.” It was processed fast. A human radiolabeled resveratrol study found high absorption after an oral dose, yet extensive conversion into metabolites rather than sustained free resveratrol.

The story is not automatically bad. Some metabolites may have their own activity, and some tissues may be able to remove the tags locally. But that is a different claim from “this product gives high free resveratrol.” Current reviews treat the metabolite story as important but still not a free pass for every supplement claim.

Why formulation claims matter, but do not erase the problem

Some products try to improve resveratrol exposure by changing particle size, combining it with fats, or using special delivery systems. The clearest named example is SRT501, a micronized resveratrol formulation. Micronized means the particles are made smaller so they disperse and dissolve more easily. In a small trial in people with colorectal cancer spread to the liver, 5 g per day of SRT501 produced plasma resveratrol levels about 3.6 times higher than published levels for the same dose of nonmicronized resveratrol, and resveratrol was detected in liver tissue.

That result shows formulation can matter. It does not show that every “enhanced absorption” label delivers meaningful tissue effects, and it does not turn ordinary resveratrol into a proven treatment. The practical decision is simple: if you are comparing resveratrol products, give more weight to human blood-level data for that exact formulation than to the milligram dose on the front label. A 250 mg product with credible human exposure data tells you more than a 1,000 mg product with only a slogan.